LXRX Insider Trading Activity and SEC Form 4 Filings
LXRX insider trading summary
Over the past 12 months, insiders at Lexicon Pharmaceuticals, Inc. (LXRX) reported 15 open-market purchases worth $18.6M by 9 insiders and no sales on SEC Form 4. Net insider buying was $18.6M.
Latest LXRX insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Feb 25, 2026 | Raymond Debbane | Director | Buy | $3K (2,000 @ $1.49) |
| Feb 20, 2026 | Raymond Debbane | Director | Buy | $148K (100,000 @ $1.48) |
| Feb 19, 2026 | Raymond Debbane | Director | Buy | $72K (50,000 @ $1.44) |
| Feb 18, 2026 | Raymond Debbane | Director | Buy | $176K (133,688 @ $1.32) |
| Feb 17, 2026 | Raymond Debbane | Director | Buy | $101K (76,857 @ $1.31) |
| Feb 13, 2026 | Raymond Debbane | Director | Buy | $76K (57,952 @ $1.31) |
| Feb 2, 2026 | Artal International Management S.A. | Insider | Buy | $2.0M (1,538,462 @ $1.30) |
| Feb 2, 2026 | International S.C.A. Artal | Insider | Buy | $2.0M (1,538,462 @ $1.30) |
| Feb 2, 2026 | Administratiekantoor Westend Stichting | Insider | Buy | $2.0M (1,538,462 @ $1.30) |
| Feb 2, 2026 | Siren, L.L.C. | Insider | Buy | $2.0M (1,538,462 @ $1.30) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.